Oleander Phoenix Biotechnology executes a second amendment to its Sponsored Research Agreement with M. D. Anderson Cancer Center. Posted on September 2008June 2022 by Carlos Torres 06 Sep Publication: Determinants of human and mouse melanoma cell sensitivities to oleandrin. Lin Y, Dubinsky WP, Ho DH, Felix E, Newman RA. J Exp Ther Oncol. 2008;7(3):195-205. PMID: 19066128 Phoenix raises >$3,000,000 from angel investors. Phoenix Biotechnology executes a Sponsored Research Agreement with Duke University for in vitro research in neurological disorders using PBI-05204 and certain discrete fractions of the whole extract.